<div id="readability-page-1"><p><span>Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report)</span> was upgraded by investment analysts at Wall Street Zen from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note issued on Saturday.</p><div><p><span></span><span>Get <strong>Taysha Gene Therapies</strong> alerts:</span></p></div><ul><li>Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?&#34;</li></ul><p>A number of other research analysts also recently issued reports on TSHA. Raymond James Financial began coverage on shares of Taysha Gene Therapies in a research report on Tuesday, October 21st. They set a &#34;strong-buy&#34; rating and a $13.00 target price on the stock. JMP Securities  set a $8.00 price target on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Taysha Gene Therapies in a research report on Monday. Citigroup  restated an &#34;outperform&#34; rating on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. Finally, Robert W. Baird upped their price target on Taysha Gene Therapies from $7.00 to $12.00 and gave the stock an &#34;outperform&#34; rating in a research note on Thursday, October 2nd. One analyst  has rated the stock with a Strong Buy rating, eleven have assigned  a Buy rating and one  has assigned  a Sell rating to the company. According to MarketBeat.com, the stock  has an average rating of &#34;Moderate Buy&#34; and an average price target of $10.42.</p><p><b>View Our Latest Research Report on TSHA</b></p><h2>Taysha Gene Therapies Stock Up 0.5%</h2><ul><li>3 Small-Cap Stocks For Your Fall Shopping List</li></ul><p>Shares of Taysha Gene Therapies stock opened at $5.79 on Friday. The stock's 50-day moving average is $4.69 and its 200 day moving average is $3.47. Taysha Gene Therapies has a one year low of $1.05 and a one year high of $5.95. The firm has a market cap of $1.59 billion, a price-to-earnings ratio of -17.55 and a beta of 1.06. The company has a debt-to-equity ratio of 0.23, a current ratio of 10.48 and a quick ratio of 10.48. </p><p>Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. Equities research analysts anticipate that  Taysha Gene Therapies will post -0.35 EPS for the current year. </p><h2>Insider Buying and Selling at Taysha Gene Therapies</h2><p>In related news, insider Sukumar Nagendran sold 260,047 shares of the firm's stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $4.51, for a total value of $1,172,811.97. Following the transaction, the insider owned 1,006,439 shares of the company's stock, valued at approximately $4,539,039.89. This trade represents a 20.53% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. 3.78% of the stock is owned by corporate insiders. </p><h2>Institutional Trading of Taysha Gene Therapies</h2><p>A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TSHA. Vanguard Group Inc. lifted its holdings in shares of  Taysha Gene Therapies by 17.9% in the third quarter. Vanguard Group Inc. now owns 12,849,613 shares of the company's stock valued at $42,018,000 after purchasing an additional 1,955,486 shares in the last quarter.  Octagon Capital Advisors LP grew its holdings in  Taysha Gene Therapies by 17.7% during the second quarter. Octagon Capital Advisors LP now owns 12,592,500 shares of the company's stock worth $29,089,000 after buying an additional 1,892,500 shares in the last quarter.  Jefferies Financial Group Inc. raised its position in  Taysha Gene Therapies by 4,105.3% in the 2nd quarter. Jefferies Financial Group Inc. now owns 10,313,733 shares of the company's stock valued at $23,825,000 after buying an additional 10,068,479 shares during the last quarter.  Vestal Point Capital LP lifted its stake in  Taysha Gene Therapies by 83.3% during the 3rd quarter. Vestal Point Capital LP now owns 5,500,000 shares of the company's stock valued at $17,985,000 after acquiring an additional 2,500,000 shares in the last quarter.  Finally, Polar Capital Holdings Plc boosted its holdings in  Taysha Gene Therapies by 5.9% during the 3rd quarter. Polar Capital Holdings Plc now owns 5,293,879 shares of the company's stock worth $17,311,000 after acquiring an additional 293,879 shares during the last quarter. 77.70% of the stock is owned by institutional investors. </p><h2>Taysha Gene Therapies Company Profile</h2> (Get Free Report)<p>Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.</p><h2>See Also</h2><ul><li>Five stocks we like better than Taysha Gene Therapies</li><li>Mastering Discipline: Overcoming Emotional Challenges In Trading</li><li>Synopsys Sees Bullish Shift as Ansys Integration Drives Growth</li><li>How to Most Effectively Use the MarketBeat Earnings Screener</li><li>The Best Holiday Present You Can Give Yourself? Costco Stock</li><li>The 3 Best Fintech Stocks to Buy Now</li><li>Why Zscaler Stock Could Be Ready to Bounce After a 30% Selloff</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Taysha Gene Therapies Right Now?</h2><p>Before you consider Taysha Gene Therapies, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Taysha Gene Therapies wasn't on the list.</p><p>While Taysha Gene Therapies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

TSHA

<p>Wall Street Zen upgraded Taysha Gene Therapies (NASDAQ:TSHA) from a "sell" to a "hold" rating. Other analysts have varied ratings, with some assigning "strong-buy" and "outperform" ratings. The stock opened at $5.79, with a market cap of $1.59 billion. Institutional investors, including Vanguard and Jefferies, have increased their stakes in the company. Insider trading activity was noted, with a significant sale by an insider. The company focuses on gene therapies for monogenic diseases.</p>

Taysha Gene Therapies (NASDAQ:TSHA) Rating Increased to Hold at Wall Street Zen